SCHEMBL3358712

SCHEMBL3358712

CC(C)(C)OC(=O)[C@@]1(COc2cncc(-c3cccc(CCCNS(C)(=O)=O)c3)c2)CCN1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 4/20 0.38
ROCK2 O75116 2/20 0.38
MAP4K4 O95819 2/20 0.38
PIM1 P11309 2/20 0.38
PRKACA P17612 2/20 0.38
CDK2 P24941 2/20 0.38
GSK3B P49841 2/20 0.38
HIPK2 Q9H2X6 2/20 0.38
DYRK3 O43781 1/20 0.38
PRKD3 O94806 1/20 0.38
CDK1 P06493 1/20 0.38
ROS1 P08922 1/20 0.38
RPS6KB1 P23443 1/20 0.38
CLK2 P49760 1/20 0.38
IRAK1 P51617 1/20 0.38
RPS6KA3 P51812 1/20 0.38
PRKX P51817 1/20 0.38
CDK5 Q00535 1/20 0.38
PRKCD Q05655 1/20 0.38
MAP4K2 Q12851 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2185728 0.88 BACE1 (0.34) AKT1NR1H2SLC5A1BACE1
SCHEMBL2184886 0.81 SLC5A1 (0.31) SLC5A1
SCHEMBL2307750 0.79 AKT1 (0.38) AKT1ROCK2MAP4K4PIM1PRKACA
SCHEMBL3358714 0.78 CHRNB1 (0.40) AKT1ROCK2MAP4K4PIM1PRKACA
SCHEMBL2184835 0.76 CHRNB2 (0.33) NR1H2
SCHEMBL3355800 0.75 CHRNB2 (0.57) AKT1ROCK2MAP4K4PIM1PRKACA
SCHEMBL2185542 0.75 AKT1 (0.36) AKT1ROCK2SLC5A1
SCHEMBL2186288 0.73 CYP4F2 (0.40) AKT1SLC5A1
SCHEMBL2300520 0.71 DGAT1 (0.37)
SCHEMBL2185877 0.70 CFD (0.44) AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445684-B2 Nicotinic acetylcholine receptor ligands and the uses thereof PsycoGenics Inc. (US) 2013-05-21 US disclosed
US-20100152450-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF PSYCHOGENICS, INC. (US) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152450-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF CHRNG, CHRNA5, CHRNA2 AKT1 3276/4885ROCK2 2471/4885MAP4K4 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.